Is BlackRock a Buy, Sell or Hold
With a large suite of ETF offerings as well as…
Sell
18
IOBT Quote, Financials, Valuation and Earnings
Last price:
$0.86
Seasonality move
:
-23.85%
Day range:
$0.86 - $0.92
52-week range:
$0.66 - $1.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.21x
Volume:
41.3K
Avg. volume:
199K
1-year change:
-42.66%
Market cap:
$56.7M
Revenue:
--
EPS (TTM):
-$1.37
Analysts' Opinion
-
Consensus RatingIO Biotech has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.00, IO Biotech has an estimated upside of 946.39% from its current price of $0.86.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $0.86.
Fair Value
-
According to the consensus of 2 analysts, IO Biotech has 946.39% upside to fair value with a price target of $9.00 per share.
IOBT vs. S&P 500
-
Over the past 5 trading days, IO Biotech has overperformed the S&P 500 by 1.8% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
IO Biotech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IO Biotech has grown year-over-year revenues for 0 quarters straight. In the most recent quarter IO Biotech reported revenues of --.
Earnings Growth
-
IO Biotech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter IO Biotech reported earnings per share of -$0.36.
Enterprise value:
-3.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.04x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$71.4M | -$91.4M | -$95.2M | -$28.2M | -$26.9M | |
| EBITDA | -$69.3M | -$90.7M | -$94.3M | -$28M | -$26.7M | |
| Diluted EPS | -$2.48 | -$2.16 | -$1.45 | -$0.40 | -$0.48 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.6M | $221.7M | $148.2M | $147.3M | $65M | |
| Total Assets | $5.7M | $222.3M | $151.8M | $150.7M | $67.7M | |
| Current Liabilities | $3.1M | $10.3M | $10.7M | $15.7M | $19.5M | |
| Total Liabilities | $41M | $10.4M | $13M | $17.6M | $20.7M | |
| Total Equity | -$35.3M | $211.9M | $138.9M | $133.2M | $47M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$59.7M | -$71.7M | -$82.3M | -$22.8M | -$19.6M | |
| Cash From Investing | -$690K | -$323K | -$44K | -$112K | -$11K | |
| Cash From Financing | -- | $71.9M | -- | -$10K | -- | |
| Free Cash Flow | -$60.4M | -$72.1M | -$82.4M | -$22.9M | -$19.6M | |
IOBT
Sector
Market Cap
$56.7M
$35M
Price % of 52-Week High
48.05%
42.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-42.66%
-41.61%
Beta (5-Year)
--
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.87
200-day SMA
Sell
Level
$1.06
Bollinger Bands (100)
Sell
Level
0.82 - 1
Chaikin Money Flow
Sell
Level
-23.8M
20-day SMA
Sell
Level
$0.98
Relative Strength Index (RSI14)
Sell
Level
41.67
ADX Line
Sell
Level
16.04
Williams %R
Buy
Level
-91.834
50-day SMA
Sell
Level
$0.96
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Sell
Level
-3.8M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Stock Forecast FAQ
In the current month, IOBT has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IOBT average analyst price target in the past 3 months is $9.00.
-
Where Will IO Biotech Stock Be In 1 Year?
According to analysts, the consensus estimate is that IO Biotech share price will rise to $9.00 per share over the next 12 months.
-
What Do Analysts Say About IO Biotech?
Analysts are divided on their view about IO Biotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IO Biotech is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is IO Biotech's Price Target?
The price target for IO Biotech over the next 1-year time period is forecast to be $9.00 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IOBT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IO Biotech is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IOBT?
You can purchase shares of IO Biotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IO Biotech shares.
-
What Is The IO Biotech Share Price Today?
IO Biotech was last trading at $0.86 per share. This represents the most recent stock quote for IO Biotech. Yesterday, IO Biotech closed at $0.86 per share.
-
How To Buy IO Biotech Stock Online?
In order to purchase IO Biotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy, Sell or Hold?
Uber (NYSE:UBER) has been through quite a ride over the…
Is Micron a Good Stock to Buy Now?
Like most of its peers in the semiconductor industry, Micron…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 18
UnitedHealth Group [UNH] is down 22.4% over the past day.
Sell
32
MAN alert for Apr 18
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 18
Global Payments [GPN] is down 17.44% over the past day.
